PCSA Acquires Vidya Therapeutics
PCSA buys Vidya Therapeutics for BTK inhibitor
Story updates
11:31:05 AM UTC
SquawkNews
PCSA Processa Pharmaceuticals, Inc. announces acquisition of vidya Therapeutics, Inc. and approximately $200M concurrent private placement to advance btk inhibitor, vt-7208, in multiple disease areas
11:31:27 AM UTC
SquawkNews
PCSA PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREAS
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.